Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Researcher at Aberdeen life sciences firm Elasmogen lands £2m fellowship

Future Leaders Fellow Obinna Ubah.
Future Leaders Fellow Obinna Ubah.

North-east expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with a prestigious research fellowship worth £2 million.

The recognition for Obinna Ubah, of Aberdeen University spin-out Elasmogen, is part of UK Research and Innovation (UKRI) Future Leaders Fellowship Scheme funding – worth more than £16.5m – to support Scotland’s most promising scientists.

I can’t wait to get started with the task of developing some of the exciting science innovation that has been funded.”

Obinna Ubah, Elasmogen.

A total of 97 of the UK’s most talented researchers are sharing a £113.5m pot to help bring their innovative ideas from lab to market, and provide “bold solutions” to tackle major global issues ranging from climate change and chronic disease to hate speech.

Mr Ubah, whose achievements to date include an Aberdeen University postgraduate degree in cellular and molecular biology, leads Elasmogen’s auto-immune and anti-inflammation research efforts.

Pioneering research

His new fellowship involves a £1.57m grant from UK Government-backed UKRI to take forward his pioneering studies.

He and his research team have isolated a new class of super-neutralising biologics, whose building blocks were originally derived from a blood sample taken from a shark.

It is believed these have the potential to be 10 times more effective than existing therapies for conditions such as rheumatoid arthritis and inflammatory bowel disease (IBD).

They have also shown promise for reducing some of the side-effects experienced by patients on long-term therapy.

Mr Ubah can now go further and faster with his groundbreaking research.

He hopes to make additional improvements so the drugs can neutralise more than one target at a time, minimising the chance that therapies will fail.

There is also potential for research partnerships to develop them into pills that can be taken at home, rather than the current need for repeated hospital visits and injections.

“I am enormously grateful to have successfully secured this UKRI fellowship”, Mr Ubah said.

Long journey

He added: “It was a long application journey, which started in March of 2020 and was complicated by the global pandemic and lockdowns.

“Now I can’t wait to get started with the task of developing some of the exciting science innovation that has been funded, and attempt to deliver safer and more effective biologics (protein-based) treatments for some of the most debilitating autoimmune, inflammatory diseases.”


Opportunity North East accelerates more life sciences research spin-outs


The management of chronic inflammatory diseases such as IBD, psoriasis, and RA has significantly improved over the past decade with the clinical availability of biologic drugs.

Mr Ubah said: “Despite this undoubted treatment success, a combination of acquired resistance together with an increased risk of systemic complications means that a significant number of patients either fail to find a suitable therapy or, frustratingly, discover that an approach that did work is no longer effective.”

‘A great outcome’

Elasmogen chief executive Caroline Barelle said the company “could not be more proud” of Mr Ubah’s achievements.

She added: “This fellowship is a fitting reward for all his hard work, the innovative approaches he has taken in his research and the global network of colleagues he has established that are eager to collaborate, mentor and form partnerships.

“This is not only a great outcome for Dr Ubah but also for Elasmogen, Aberdeen and Scotland.

“The success of Dr Ubah’s award reinforces Aberdeen city as a centre of excellence in business-led drug discovery, and biologics in particular.”

Elasmogen chief executive Caroline Barelle.

Scotland Office Minister Iain Stewart said: “We are proud to support such a diverse and worthwhile range of projects.

“This research will make a real difference to people’s lives, from potentially saving the sight of millions to finding new treatments for disease and creating environmentally-friendly smart tech.

“Scottish scientists have long been pioneers of innovation and this investment will encourage a new generation of trailblazers to keep that tradition going.”


Life sciences playing a vital role in Covid-19 crisis